Multiple Sclerosis Clinical Trials in Los Angeles

Showing 321-340 of 489 trials

Preparing to Run Effective Prevention

NCT02135991

Young people can engage in a variety of negative behaviors-such as drug use, underage drinking, and premarital sex-that exact a high toll on local communities. These activities are often the target of community-based prevention efforts. Getting To Outcomes (GTO) is an approach that includes a toolkit, technical assistance, and training, organized around a 10-step process, that helps communities plan, implement, and evaluate the impact of their programs that attempt to prevent these negative behaviors. This study will examine the degree to which Getting To Outcomes helps Boys and Girls Clubs implement an evidence based drug prevention program.

Implementation of Evidence Based Programs

RAND990 participantsStarted Sep 2013

Buena Park, California, United States • Burbank, California, United States • Carson, California, United States +12 more locations

COMPLETEDPhase 3< 1 mile

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

NCT00375674

To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.

Kidney Neoplasms

Pfizer674 participantsStarted Aug 2007

Los Angeles, California, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +112 more locations

Preparing to Run Effective Prevention

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Multiple Sclerosis Trials in Other Cities

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

TR(ACE) Assay Clinical Specimen Study

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Other Conditions in Los Angeles